Towards this goal, we recently developed a dual inhibitor of CK2 and CDK4/6, ON108110, and examined its effects on the growth and apoptosis of MCL and T-ALL cell lines. This evidence concerns the gene CDK4 and acute lymphoblastic leukemia.